XBiotech Inc. financial data

Symbol
XBIT on Nasdaq
Location
Austin, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 22.77 % +63.7%
Debt-to-equity 0.05 % -34.9%
Return On Equity -0.17 % -4.6%
Return On Assets -0.16 % -7.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30,487,731 shares +0.01%
Common Stock, Shares, Outstanding 30,487,731 shares +0.03%
Entity Public Float 121,869,724 USD -13.2%
Common Stock, Value, Issued 276,565,000 USD +1.5%
Weighted Average Number of Shares Outstanding, Basic 30,487,731 shares +0.05%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 29,856,000 USD -20.9%
General and Administrative Expense 4,825,000 USD +5.6%
Operating Income (Loss) -34,681,000 USD +18%
Nonoperating Income (Expense) 5,643,000 USD -41%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -29,038,000 USD +11.3%
Income Tax Expense (Benefit) 118,000 USD +10.3%
Net Income (Loss) Attributable to Parent -29,156,000 USD +10.7%
Earnings Per Share, Basic 0 USD/shares +10.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 147,367,000 USD -19.5%
Accounts Receivable, after Allowance for Credit Loss, Current 450,000 USD -38.4%
Assets, Current 148,951,000 USD -19.5%
Property, Plant and Equipment, Net 23,473,000 USD -5.4%
Assets 172,424,000 USD -17.8%
Accounts Payable, Current 1,043,000 USD -30.7%
Employee-related Liabilities, Current 611,000 USD +8.7%
Accrued Liabilities, Current 2,422,000 USD -46%
Liabilities, Current 3,565,000 USD -77.7%
Accrued Income Taxes, Noncurrent 1,779,000 USD +2%
Deferred Income Tax Liabilities, Net 0 USD -100%
Liabilities 5,344,000 USD -69.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) -109,485,000 USD -36.3%
Stockholders' Equity Attributable to Parent 167,080,000 USD -13%
Liabilities and Equity 172,424,000 USD -17.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6,720,000 USD +6.7%
Net Cash Provided by (Used in) Financing Activities -10,250,000 USD -2%
Net Cash Provided by (Used in) Investing Activities -94,000 USD +63.1%
Common Stock, Shares, Issued 30,487,731 shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16,780,000 USD -17.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 486,000 USD +21.5%
Deferred Tax Assets, Valuation Allowance 26,382,000 USD +50.1%
Deferred Tax Assets, Gross 26,777,000 USD +47.1%
Depreciation 442,000 USD +2.3%
Payments to Acquire Property, Plant, and Equipment 94,000 USD -63.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -38,531,000 USD -51.8%
Deferred Tax Assets, Operating Loss Carryforwards 2,799,000 USD +1.2%
Unrecognized Tax Benefits 3,434,000 USD +15.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 395,000 USD -37.1%
Share-based Payment Arrangement, Expense 4,088,000 USD +1.3%